Description: CD19 is a transmembrane glycoprotein that contains two extracellular immunoglobulin-like domains. CD19 is present in both benign and malignant B-cells and is considered to be the most reliable surface marker of this lineage over a wide range of maturational stages. In normal lymphoid tissue, CD19 is observed in germinal centers, in mantle zone cells, and in scattered cells of the inter-follicular areas. Anti-CD19 exhibits an overall immunoreactivity pattern similar to those of the antibodies against CD20 and CD22. However, in contrast to CD20, expression of CD19 is continuous throughout B-cell development and through terminal differentiation of B-cells into plasma cells. Anti-CD19 positivity is seen in the vast majority of B-cell neoplasms commonly at a lower intensity than normal B-cell counterparts. Plasma cell neoplasms are nearly always negative, as are T-cell neoplasms.Primary antibodies are available purified, or with a selection of fluorescent CF® Dyes and other labels. CF® Dyes offer exceptional brightness and photostability. Note: Conjugates of blue fluorescent dyes like CF®405S and CF®405M are not recommended for detecting low abundance targets, because blue dyes have lower fluorescence and can give higher non-specific background than other dye colors.
Product origin: Animal - Mus musculus (mouse), Bos taurus (bovine)
Conjugate: CF740
Concentration: 0.1 mg/mL
Storage buffer: PBS, 0.1% rBSA, 0.05% azide
Clone: CVID3/429
Immunogen: Recombinant human CD19 protein
Antibody Reactivity: CD19
Entrez Gene ID: 930
Z-Antibody Applications: Flow, surface (verified)/IF (verified)
Verified AB Applications: Flow (surface) (verified)/IF (verified)
Antibody Application Notes: Higher concentration may be required for direct detection using primary antibody conjugates than for indirect detection with secondary antibody/Immunofluorescence: 0.5-1 ug/mL/Flow Cytometry 0.5-1 ug/million cells/0.1 mL/Optimal dilution for a specific application should be determined by user
Deutsch
English
